UOC Ematologia, Azienda Ospedaliero-Universitaria Policlinico S.Orsola-Malpighi,
Welcome,         Profile    Billing    Logout  
 4 Trials 
10 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Cavo, Michele
DREAMM8, NCT04484623 / 2018-004354-21: Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma

Jan 2024 - Dec 2024: Market entry for 2L multiple myeloma (based on DREAMM-7 trial)
Hourglass Oct 2024 - Dec 2024 : Acceptance of regulatory submission in US for 2L+ multiple myeloma
Hourglass Jul 2024 - Dec 2024 : Acceptance of regulatory submission in EU for 2L+ multiple myeloma (based on DREAMM-8 trial)
Jan 2024 - Dec 2024: Regulatory approval in US for 2L+ multiple myeloma (based on DREAMM-7 trial)
Jan 2024 - Dec 2024: Regulatory approval in EU for 2L+ multiple myeloma (based on DREAMM-7 trial)
More
Recruiting
3
357
Europe, Japan, US, RoW
Belantamab mafodotin, Pomalidomide, Dexamethasone, Bortezomib
GlaxoSmithKline
Multiple Myeloma
01/24
05/29
DREAMM 14, NCT05064358 / 2021-004151-16: Study to Investigate Alternative Dosing Regimens of Belantamab Mafodotin in Participants With Relapsed or Refractory Multiple Myeloma

Hourglass Jul 2024 - Dec 2024 : Data for RRMM
Active, not recruiting
2
177
Europe, Canada, US, RoW
Belantamab mafodotin
GlaxoSmithKline
Multiple Myeloma
08/24
02/25
iinnovate-1, NCT03215030 / 2021-006038-37: A Study of Modakafusp Alfa on Adult Participants With Relapsed/Refractory Multiple Myeloma

Completed
1/2
272
Europe, Canada, Japan, US, RoW
Modakafusp alfa, TAK-573, TEV-48573, Dexamethasone
Takeda, Takeda Development Center Americas, Inc.
Multiple Myeloma
07/24
11/24
ZN-d5-003, NCT05199337 / 2021-003008-42: Phase 1/2 Study of ZN-d5 for the Treatment of Relapsed or Refractory Light Chain (AL) Amyloidosis

Completed
1/2
18
Europe, US, RoW
ZN-d5, Study Drug
K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc., K-Group Alpha, Inc
Amyloidosis, AL Amyloidosis
02/24
02/24
NCT04643002 / 2020-003024-16: Isatuximab in Combination With Novel Agents in RRMM - Master Protocol

Recruiting
1/2
258
Europe, US, RoW
Isatuximab, SAR650984, Sarclisa®, Dexamethasone, Pomalidomide, Pomalyst®, Belantamab mafodotin, BLENREP®, Pegenzileukin, SAR444245, SAR439459, Belumosudil, SAR445761,, Rezurock, Evorpacept, ALX148
Sanofi
Plasma Cell Myeloma Refractory
07/27
03/28
DREAMM 9, NCT04091126 / 2019-003047-30: Study of Belantamab Mafodotin Plus Standard of Care (SoC) in Newly Diagnosed Multiple Myeloma

Checkmark From DREAMM-9 trial for 1L transplant ineligible multiple myeloma at ASH 2021
Dec 2021 - Dec 2021: From DREAMM-9 trial for 1L transplant ineligible multiple myeloma at ASH 2021
Recruiting
1
144
Europe, Canada, US, RoW
Belantamab mafodotin, Bortezomib, Lenalidomide, Dexamethasone
GlaxoSmithKline
Multiple Myeloma
11/24
06/25
NCT04352556: COVID19-hematological Malignancies: the Italian Hematology Alliance

Recruiting
N/A
250
Europe
Ospedale di Circolo - Fondazione Macchi
SARS-CoV-2 Infection, Hematological Malignancies
10/22
10/22
MY MYELOMA, NCT05001087: A "Physician & Patient-powered" Cohort Registry

Recruiting
N/A
1900
Europe
Observation
Fondazione EMN Italy Onlus
Multiple Myeloma
03/24
03/24
CLARITY, NCT03190525: Clinical Decision-making, Prognosis, Quality of Life and Satisfaction in Relapsed/Refractory Multiple Myeloma

Recruiting
N/A
520
Europe
Quality of life questionnaires
Gruppo Italiano Malattie EMatologiche dell'Adulto
Multiple Myeloma
12/24
12/24
IONA-MM, NCT04458831: A Prospective, Non-interventional, Multinational, Observational Study With Isatuximab in Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM)

Active, not recruiting
N/A
586
Europe, Japan, US, RoW
isatuximab SAR650984, Sarclisa, Pomalidomide, Pomalyst, Dexamethasone, Carfilzomib
Sanofi
Plasma Cell Myeloma
02/26
02/26

Download Options